| http://www.w3.org/ns/prov#value | - The FDA recommends that patients with end-stage kidney disease who receive erythropoiesis-stimulating drugs should:Maintain hemoglobin levels between 10 - 12 g/dLReceive frequent blood tests to monitor hemoglobin levelsContact their doctors if they experience such symptoms as shortness of breath, pain, swelling in the legs, or increases in blood pressure
|
